Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Clinical trial: Patients with locally advanced, muscle-invasive bladder cancer do not benefit from extended lymph node removal.

2.

Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients

3.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

4.

Prostate cancer death risk is higher in late teens and early 20s weight gain.

5.

Gotistobart Response Rate Bests Chemo in Pretreated NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot